CollPlant director Alisa Lask discloses equity awards

Q: What is the vesting schedule for Alisa Lask’s CollPlant (CLGN) restricted share units?

Out of 10,000 restricted share units, 3,125 are already vested. The remaining 6,875 vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on her continued service with CollPlant at each vesting date.

CollPlant Biotechnologies Ltd director Alisa Lask reports existing equity awards, including options and restricted share units.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd director Alisa Lask reports existing equity awards, including options and restricted share units. She holds options to purchase 47,000 Ordinary Shares at an exercise price of $6.39 per share, expiring on May 2, 2032, all held directly.

The Form 3 also reports 10,000 restricted share units held directly. According to the footnotes, 3,125 of these units are vested and 6,875 will vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Of the options, 44,062 are already vested and 2,938 are scheduled to vest on May 2, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lask Alisa

Role Director

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 47,000 contracts (Direct); Restricted Share Units — 10,000 shares (Direct)

Footnotes (2)

F1. Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F2. 44,062 options are fully vested and exercisable and the remaining 2,938 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider holdings does CollPlant (CLGN) director Alisa Lask report on this Form 3?

Alisa Lask reports existing equity awards, not new trades. She holds options to purchase 47,000 CollPlant Ordinary Shares at an exercise price of $6.39 and 10,000 restricted share units, all reported as directly owned equity interests.

How many CollPlant (CLGN) options does Alisa Lask hold and what is the exercise price?

She holds options to purchase 47,000 Ordinary Shares at an exercise price of $6.39 per share. These options are scheduled to expire on May 2, 2032, providing a long-dated derivative position linked to CollPlant’s Ordinary Shares.

What portion of Alisa Lask’s CollPlant (CLGN) options are currently vested?

Footnotes state that 44,062 of her options are fully vested and exercisable. The remaining 2,938 options are scheduled to vest on May 2, 2026, assuming she continues to serve CollPlant through that specified vesting date.

Does this CollPlant (CLGN) Form 3 show any insider buying or selling by Alisa Lask?

The Form 3 reports holdings rather than new trades. It lists her existing options and restricted share units, with no open-market purchases or sales indicated. Transaction summary data classifies both entries as holdings with unknown transaction codes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 10:22 AM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lask Alisa

(Last)

(First)

(Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT

7670104

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units	10,000⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options to Purchase Ordinary Shares⁽²⁾	05/02/2023	05/02/2032	Ordinary Shares	47,000⁽²⁾	$6.39	D

Explanation of Responses:

1. Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

2. 44,062 options are fully vested and exercisable and the remaining 2,938 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Alisa Lask	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR